-

09:47:44 AM

PHVS Stock News

PHVS - Pharvaris NV

03/18/23 12:35 AM

Nasdaq : PHVS

clinical triallow float

Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks Highlighted at the 2023 HAEi Regional Conference APAC

Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced an oral presentation of positive data from its Phase 2

RHEA-AI

neutral

03/02/23 6:50 AM

Nasdaq : PHVS

conferenceslow float

Pharvaris to Present in Upcoming March Investor Conferences

Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced that management will participate in two upcoming investor

RHEA-AI

neutral

02/24/23 6:50 AM

Nasdaq : PHVS

clinical triallow float

Pharvaris to Highlight Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks at AAAAI Annual Meeting

Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced a poster detailing positive data from its Phase 2 RAPIDe-1

RHEA-AI

neutral

02/08/23 6:50 AM

Nasdaq : PHVS

conferenceslow float

Pharvaris to Present at SVB Securities Global Biopharma Conference

Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced that management will present at the SVB Securities Global

RHEA-AI

neutral

01/09/23 6:50 AM

Nasdaq : PHVS

low float

Pharvaris Provides Regulatory, Clinical, and Corporate Updates

Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today provided business updates and company highlights. Business Updates and

RHEA-AI

very positive

12/08/22 6:51 AM

Nasdaq : PHVS

earningslow float

Pharvaris Reports Third Quarter 2022 Financial Results and Provides Business Update

Announced positive top-line data for RAPIDe-1, a global Phase 2 study of PHVS416 for the on-demand treatment of HAE attacks Participated in a Type A meeting with the FDA regarding the previously announced holds on the clinical studies of PHA121 in the U.S. Top-line data from CHAPTER-1, a global

RHEA-AI

positive

12/08/22 6:50 AM

Nasdaq : PHVS

clinical triallow float

Pharvaris Announces Positive Top-line Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks

Pharvaris (Nasdaq: PHVS), a clinical-stage

RHEA-AI

neutral

11/10/22 8:00 AM

Nasdaq : PHVS

conferencesclinical triallow float

Pharvaris to Present PHVS416 and PHVS719 Clinical Data for Treatment of HAE at the ACAAI Annual Scientific Meeting 2022

Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced it will be presenting two in-person “ePoster – Meet the

RHEA-AI

negative

10/07/22 8:30 AM

Nasdaq : PHVS

low float

Pharvaris Presents Data Supporting HAE Drug Development Strategy at the 2022 HAEi Global Leadership Workshop

Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the presentation of preclinical and clinical data of PHA121,

RHEA-AI

neutral

09/30/22 6:50 AM

Nasdaq : PHVS

low float

Pharvaris Announces the Promotion of Annick Deschoolmeester to Chief Human Resources Officer

Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the promotion of Annick Deschoolmeester to Chief Human

RHEA-AI

neutral